PegBio Co

PegBio Co FCF Yield

The Free Cash Flow Yield of PegBio Co (2565.HK) as of Nov 19, 2026 is -0.68 %. In the previous year, Free Cash Flow Yield was -0.80 % — a change of -15.69% (higher).

FCF Yield

-0.68 %

YoY

-15.69%

Last updated:

Free Cash Flow Yield of PegBio Co is 2025 -0.68 % . Free Cash Flow Yield of PegBio Co was 2024 -0.80 % . It decreases by -15.69% higher compared to the previous year.

The PegBio Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2022
-0.76 CNY
Jan 1, 2023
-1.02 CNY
Jan 1, 2024
-0.80 CNY
Jan 1, 2025
-0.68 CNY
The PegBio Co FCF Yield history
YEARFCF YieldYoY
-0.68 %-15.69%
-0.80 %-21.11%
-1.02 %+33.98%
-0.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co., Ltd. generates revenue primarily through the development and commercialization of innovative drugs targeting chronic and metabolic diseases. The company's flagship product, PB-119, is a near-commercialized long-acting GLP-1 receptor agonist designed for treating type 2 diabetes and obesity. Product candidates such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309 are in development for indications including non-alcoholic steatohepatitis, opioid-induced constipation, and congenital hyperinsulinemia. The company focuses on pharmaceutical markets for chronic disease treatment, targeting patients and healthcare providers seeking advanced therapeutic solutions. PegBio's revenue streams are derived from the sale of PB-119 once it reaches commercialization, alongside potential future sales of its pipeline products. The firm targets healthcare systems and medical professionals in China, where it is headquartered, to address high-prevalence conditions like type 2 diabetes and obesity. Its product portfolio addresses unmet medical needs in metabolic disorders, positioning PegBio to capture market share in the growing biotechnology sector. The company's business model centers on developing proprietary drug candidates with strong clinical potential. PB-119, as a near-commercialized asset, is expected to drive initial revenue, while the broader pipeline of products like PB-718 and PB-2301 targets expanding therapeutic areas. PegBio aims to establish itself as a leader in chronic disease therapeutics through a focused approach on metabolic and endocrine conditions. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

Free Cash Flow Yield of PegBio Co is -0.68 % in 2025.

Free Cash Flow Yield of PegBio Co changed from -0.80 % to -0.68 %, representing a -15.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield PegBio Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's PegBio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — PegBio Co

All Key Metrics — PegBio Co